Issue Date: March 5, 2012
GSK And Angiochem In Rare-Diseases Pact
To bolster its rare-diseases program, GlaxoSmithKline is teaming up with Montreal-based Angiochem to develop treatments for lysosomal storage diseases. Angiochem gets an up-front payment of as much as $31.5 million plus research funding it will use to develop enzyme replacement therapies (ERTs) that can cross the blood-brain barrier. Current ERTs are unable to address the neurological symptoms caused by lysosomal storage diseases. Angiochem’s engineered-peptide technology overcomes those limitations by binding to the LRP1 receptor, which provides a gateway into the brain.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society